Publications by authors named "Hannah Onafuye"
Article Synopsis
- Willow species are known for medicinal compounds, notably salicin, which is the precursor to aspirin.
- Researchers isolated a cyclodimeric salicinoid called miyabeacin from two willow species and demonstrated its anti-cancer properties.
- The ability to produce dimers like miyabeacin is a heritable trait, and structural variations arise from specific chemical reactions involving ortho-quinol precursors within the willow's biosynthetic pathways.
Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.
Beilstein J Nanotechnol
October 2019
Article Synopsis
- Nanoparticles are being researched as a way to deliver anticancer drugs like doxorubicin, especially in cancer cells resistant to traditional treatments due to drug efflux transporters like ABCB1.
- The study produced various types of nanoparticles (PLGA, PLA, and PEGylated PLGA) with varying sizes and drug release profiles to evaluate their effectiveness against neuroblastoma, including ABCB1-expressing cells.
- Results indicated that while PLGA-PEG and certain PLGA nanoparticles showed better anticancer effects, they did not significantly improve drug efficacy in ABCB1-expressing cells compared to doxorubicin alone, highlighting the variability in effectiveness based on nanoparticle preparation methods.
Article Synopsis
- Resistance to standard drug therapies, like doxorubicin, is a significant challenge in cancer treatment, particularly in neuroblastoma cells that have developed resistance mechanisms.* -
- Doxorubicin-loaded nanoparticles were more effective at killing resistant neuroblastoma cells (UKF-NB-3VCR) compared to the regular doxorubicin solution, but had limited effectiveness on cells (UKF-NB-3DOX) with more complex resistance patterns.* -
- The study suggests that using nanoparticles could be a promising approach to bypass drug resistance mechanisms associated with the ABCB1 transporter, offering a more targeted treatment option compared to traditional inhibitors that have shown limited success in clinical trials.*